Fate Therapeutics, Inc. (FATE)
2.34
-0.09
(-3.70%)
USD |
NASDAQ |
Sep 24, 16:00
2.34
0.00 (0.00%)
After-Hours: 17:49
Fate Therapeutics Enterprise Value : 205.47M for Sept. 23, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 23, 2026 | 205.47M |
| September 22, 2026 | 222.98M |
| September 21, 2026 | 217.14M |
| September 18, 2026 | 217.14M |
| September 17, 2026 | 215.98M |
| September 16, 2026 | 206.64M |
| September 15, 2026 | 196.14M |
| September 14, 2026 | 194.97M |
| September 11, 2026 | 191.47M |
| September 10, 2026 | 193.81M |
| September 09, 2026 | 206.64M |
| September 08, 2026 | 213.64M |
| September 04, 2026 | 211.31M |
| September 03, 2026 | 204.31M |
| September 02, 2026 | 207.81M |
| September 01, 2026 | 205.47M |
| August 31, 2026 | 200.81M |
| August 28, 2026 | 205.47M |
| August 27, 2026 | 218.31M |
| August 26, 2026 | 221.81M |
| August 25, 2026 | 219.48M |
| August 24, 2026 | 206.64M |
| August 21, 2026 | 193.81M |
| August 20, 2026 | 207.81M |
| August 19, 2026 | 231.15M |
| Date | Value |
|---|---|
| August 18, 2026 | 220.64M |
| August 17, 2026 | 227.65M |
| August 14, 2026 | 221.81M |
| August 13, 2026 | 215.98M |
| August 12, 2026 | 239.32M |
| August 11, 2026 | 241.65M |
| August 10, 2026 | 243.98M |
| August 07, 2026 | 248.65M |
| August 06, 2026 | 212.48M |
| August 05, 2026 | 225.31M |
| August 04, 2026 | 221.81M |
| August 03, 2026 | 213.64M |
| July 31, 2026 | 207.81M |
| July 30, 2026 | 214.81M |
| July 29, 2026 | 197.31M |
| July 28, 2026 | 192.64M |
| July 27, 2026 | 205.47M |
| July 24, 2026 | 203.14M |
| July 23, 2026 | 215.98M |
| July 22, 2026 | 222.98M |
| July 21, 2026 | 252.15M |
| July 20, 2026 | 248.07M |
| July 17, 2026 | 246.32M |
| July 16, 2026 | 240.48M |
| July 15, 2026 | 270.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 622.63M |
| Amgen, Inc. | 262.85B |
| Anika Therapeutics, Inc. | 259.52M |
| BioCryst Pharmaceuticals, Inc. | 2.671B |
| Imunon, Inc. | 7.840M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.16M |
| Revenue (Quarterly) | 2.082M |
| Total Expenses (Quarterly) | 32.24M |
| EPS Diluted (Quarterly) | -0.2505 |
| Gross Profit Margin (Quarterly) | -33.53% |
| Profit Margin (Quarterly) | -1.45K% |
| Earnings Yield | -45.00% |
| Normalized Earnings Yield | -44.85 |